Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK

Authors: Jie Luo, Xin Sun, Feng Gao, Xiaoliang Zhao, Biao Zhong, Hong Wang, Zhijun Sun

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Objective

To investigate the effects of ulinastatin and docetaxel on invasion of breast cancer cells and expression of uPA, uPAR and ERK, breast cancer MDA-MB-231 and MCF-7 cells.

Methods

The nude mice were treated with PBS, ulinastatin, docetaxel, and ulinastatin plus docetaxel, respectively. Their effects on 1) cell invasion ability was assayed using Transwell; 2) expression of uPA, uPAR and ERK was detected by real time PCR and Western blot; 3) uPA, uPAR and p-ERK protein level in nude mice was quantified by immunohistochemistry.

Results

1) Treatment with ulinastatin, docetaxel, and ulinastatin plus docetaxel, respectively, significantly inhibited MDA-MB-231 and MCF-7 cell invasion; 2) mRNA and protein levels of uPA, uPAR and ERK1/2 were inhibited by ulinastatin, but enhanced by docetaxel.

Conclusion

Ulinastatin can enhance the effects of docetaxel on invasion of breast cancer cells. And that uPA, uPAR and p-ERK expression is obviously inhibited by ulinastatin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stillfried GE, Saunders DN, Ranson M: Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007, 9 (1): R14-10.1186/bcr1647.PubMedCentralCrossRefPubMed Stillfried GE, Saunders DN, Ranson M: Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007, 9 (1): R14-10.1186/bcr1647.PubMedCentralCrossRefPubMed
2.
go back to reference Nguyen DH, Hussaini IM, Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998, 273 (14): 8502-8507. 10.1074/jbc.273.14.8502.CrossRefPubMed Nguyen DH, Hussaini IM, Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998, 273 (14): 8502-8507. 10.1074/jbc.273.14.8502.CrossRefPubMed
3.
go back to reference Aguirre GJ, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999, 147 (1): 89-104. 10.1083/jcb.147.1.89.CrossRef Aguirre GJ, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999, 147 (1): 89-104. 10.1083/jcb.147.1.89.CrossRef
4.
go back to reference Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh M: Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res. 1994, 54 (3): 844-849.PubMed Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh M: Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res. 1994, 54 (3): 844-849.PubMed
5.
go back to reference Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T: Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem. 2001, 276 (3): 2015-2022. 10.1074/jbc.M007650200.CrossRefPubMed Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T: Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem. 2001, 276 (3): 2015-2022. 10.1074/jbc.M007650200.CrossRefPubMed
6.
go back to reference Zhao Xiaoliang, Sun Xin, Gao Feng, Luo Jie, Sun Zhijun: Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-a. Journal of Experimental & Clinical Cancer Research. 2011, 30: 22-10.1186/1756-9966-30-22.CrossRef Zhao Xiaoliang, Sun Xin, Gao Feng, Luo Jie, Sun Zhijun: Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-a. Journal of Experimental & Clinical Cancer Research. 2011, 30: 22-10.1186/1756-9966-30-22.CrossRef
7.
go back to reference Sun ZJ, Yu T, Chen JS: Effects of Ulinastatin and Cyclophosphamide on the Growth of Xenograft Breast Cancer and Expression of CXCR4 and MMP-9 in Cancers. The Journal of International Medical Research. 2010, 38: 967-976.CrossRefPubMed Sun ZJ, Yu T, Chen JS: Effects of Ulinastatin and Cyclophosphamide on the Growth of Xenograft Breast Cancer and Expression of CXCR4 and MMP-9 in Cancers. The Journal of International Medical Research. 2010, 38: 967-976.CrossRefPubMed
8.
go back to reference Gao F, Sun ZJ: Progress in the correlation of vascular endothelial growth factor C and lymphangiogenesis and lymph node metastasis in breast cancer. Chongqing Medical Journal. 2010, 819-821. 07 Gao F, Sun ZJ: Progress in the correlation of vascular endothelial growth factor C and lymphangiogenesis and lymph node metastasis in breast cancer. Chongqing Medical Journal. 2010, 819-821. 07
9.
go back to reference Mahanivong C, Yu J, Huang S: Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mol Carcinog. 2007, 46 (3): 165-175. 10.1002/mc.20249.CrossRefPubMed Mahanivong C, Yu J, Huang S: Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mol Carcinog. 2007, 46 (3): 165-175. 10.1002/mc.20249.CrossRefPubMed
10.
go back to reference Sliva D, Rizzo MT, English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem. 2002, 277 (5): 3150-3157. 10.1074/jbc.M109579200.CrossRefPubMed Sliva D, Rizzo MT, English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem. 2002, 277 (5): 3150-3157. 10.1074/jbc.M109579200.CrossRefPubMed
11.
go back to reference Kanse SM, Benzakour O, Kanthou C, Christine K, Roger Lijnen H, Preissner KT: Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol. 1997, 17 (11): 2848-2854. 10.1161/01.ATV.17.11.2848.CrossRefPubMed Kanse SM, Benzakour O, Kanthou C, Christine K, Roger Lijnen H, Preissner KT: Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol. 1997, 17 (11): 2848-2854. 10.1161/01.ATV.17.11.2848.CrossRefPubMed
12.
go back to reference Konakova M, Hucho F, Schleuning WD: Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998, 253 (2): 421-429. 10.1046/j.1432-1327.1998.2530421.x.CrossRefPubMed Konakova M, Hucho F, Schleuning WD: Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998, 253 (2): 421-429. 10.1046/j.1432-1327.1998.2530421.x.CrossRefPubMed
13.
go back to reference Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE: The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998, 273 (29): 18268-18272. 10.1074/jbc.273.29.18268.CrossRefPubMed Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE: The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998, 273 (29): 18268-18272. 10.1074/jbc.273.29.18268.CrossRefPubMed
14.
go back to reference Webb DJ, Nguyen DH, Sankovic M, Gonias SL: The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem. 1999, 274 (11): 7412-7420. 10.1074/jbc.274.11.7412.CrossRefPubMed Webb DJ, Nguyen DH, Sankovic M, Gonias SL: The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem. 1999, 274 (11): 7412-7420. 10.1074/jbc.274.11.7412.CrossRefPubMed
15.
go back to reference Webb DJ, Nguyen DH, Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci. 2000, 113 (Pt 1): 123-134.PubMed Webb DJ, Nguyen DH, Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci. 2000, 113 (Pt 1): 123-134.PubMed
16.
go back to reference Yu W, Kim J, Ossowski L: Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997, 137 (3): 767-777. 10.1083/jcb.137.3.767.PubMedCentralCrossRefPubMed Yu W, Kim J, Ossowski L: Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997, 137 (3): 767-777. 10.1083/jcb.137.3.767.PubMedCentralCrossRefPubMed
17.
go back to reference Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis. 1999, 17 (8): 649-654. 10.1023/A:1006741228402.CrossRefPubMed Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis. 1999, 17 (8): 649-654. 10.1023/A:1006741228402.CrossRefPubMed
18.
go back to reference Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 1996, 14 (3): 297-307.PubMed Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 1996, 14 (3): 297-307.PubMed
19.
go back to reference Mhaidat NM, Thorne RF, Zhang XD, Hersey P: Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res. 2007, 5 (10): 1073-1081. 10.1158/1541-7786.MCR-07-0059.CrossRefPubMed Mhaidat NM, Thorne RF, Zhang XD, Hersey P: Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res. 2007, 5 (10): 1073-1081. 10.1158/1541-7786.MCR-07-0059.CrossRefPubMed
20.
go back to reference Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S: Sequence dependent exposure of mammary carcinoma cells to Docetaxel and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther. 2003, 2 (6): 670-676.CrossRefPubMed Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S: Sequence dependent exposure of mammary carcinoma cells to Docetaxel and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther. 2003, 2 (6): 670-676.CrossRefPubMed
21.
go back to reference Davies BR, Logie A, Mckay JS, Martin P, Steele S, Jenkins R: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007, 6 (8): 2209-2219. 10.1158/1535-7163.MCT-07-0231.CrossRefPubMed Davies BR, Logie A, Mckay JS, Martin P, Steele S, Jenkins R: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007, 6 (8): 2209-2219. 10.1158/1535-7163.MCT-07-0231.CrossRefPubMed
Metadata
Title
Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK
Authors
Jie Luo
Xin Sun
Feng Gao
Xiaoliang Zhao
Biao Zhong
Hong Wang
Zhijun Sun
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-71

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine